AU2013227024B2 - Novel piperidine compound or salt thereof - Google Patents

Novel piperidine compound or salt thereof Download PDF

Info

Publication number
AU2013227024B2
AU2013227024B2 AU2013227024A AU2013227024A AU2013227024B2 AU 2013227024 B2 AU2013227024 B2 AU 2013227024B2 AU 2013227024 A AU2013227024 A AU 2013227024A AU 2013227024 A AU2013227024 A AU 2013227024A AU 2013227024 B2 AU2013227024 B2 AU 2013227024B2
Authority
AU
Australia
Prior art keywords
group
methyl
compound
salt
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013227024A
Other languages
English (en)
Other versions
AU2013227024A1 (en
Inventor
Norio Masuko
Morihiro Mitsuya
Hiroshi Sootome
Tetsuya Sugimoto
Hidekazu Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2013227024A1 publication Critical patent/AU2013227024A1/en
Application granted granted Critical
Publication of AU2013227024B2 publication Critical patent/AU2013227024B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013227024A 2012-02-29 2013-02-27 Novel piperidine compound or salt thereof Active AU2013227024B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012043303 2012-02-29
JP2012-043303 2012-02-29
JP2012186534 2012-08-27
JP2012-186534 2012-08-27
PCT/JP2013/055064 WO2013129443A1 (ja) 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩

Publications (2)

Publication Number Publication Date
AU2013227024A1 AU2013227024A1 (en) 2014-09-18
AU2013227024B2 true AU2013227024B2 (en) 2015-12-10

Family

ID=49082638

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013227024A Active AU2013227024B2 (en) 2012-02-29 2013-02-27 Novel piperidine compound or salt thereof

Country Status (20)

Country Link
US (3) US9346787B2 (cg-RX-API-DMAC10.html)
EP (1) EP2821406B1 (cg-RX-API-DMAC10.html)
JP (1) JP5323289B1 (cg-RX-API-DMAC10.html)
KR (1) KR101677823B1 (cg-RX-API-DMAC10.html)
CN (1) CN104159893B (cg-RX-API-DMAC10.html)
AU (1) AU2013227024B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014021519B1 (cg-RX-API-DMAC10.html)
CA (1) CA2865875C (cg-RX-API-DMAC10.html)
DK (1) DK2821406T3 (cg-RX-API-DMAC10.html)
ES (1) ES2576497T3 (cg-RX-API-DMAC10.html)
HU (1) HUE028495T2 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN07283A (cg-RX-API-DMAC10.html)
MX (1) MX344276B (cg-RX-API-DMAC10.html)
MY (1) MY169179A (cg-RX-API-DMAC10.html)
PL (1) PL2821406T3 (cg-RX-API-DMAC10.html)
PT (1) PT2821406T (cg-RX-API-DMAC10.html)
RU (1) RU2581834C1 (cg-RX-API-DMAC10.html)
SG (1) SG11201405318PA (cg-RX-API-DMAC10.html)
TW (1) TWI485146B (cg-RX-API-DMAC10.html)
WO (1) WO2013129443A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9012475B2 (en) 2013-08-27 2015-04-21 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
KR101430209B1 (ko) * 2014-03-06 2014-08-14 강원대학교산학협력단 단백질 키나아제 활성 측정 방법 및 이를 위한 키트
TWI693218B (zh) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
CN104758286B (zh) * 2015-03-05 2016-09-14 南京工业大学 1-苄基-4-(2,4-二氯苯乙胺基)哌啶在制备抗肿瘤药物中的应用
US11028069B2 (en) 2016-12-22 2021-06-08 Taiho Pharmaceutical Co., Ltd. Salt of substituted piperidine compound
JP7227968B2 (ja) * 2018-05-29 2023-02-22 大鵬薬品工業株式会社 抗腫瘍剤及び腫瘍治療方法
CN112239465A (zh) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
CN117836285A (zh) * 2021-07-28 2024-04-05 北京加科思新药研发有限公司 Aurora a选择性抑制剂的多晶型及其用途
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
WO2024088193A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. Combination of aurora a and parp inhibitors for treatment of cancers
US20260166024A1 (en) * 2022-10-26 2026-06-18 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers
WO2024230647A1 (zh) * 2023-05-05 2024-11-14 苏州信诺维医药科技股份有限公司 杂环类化合物、其药物组合物和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2006046734A2 (ja) * 2004-10-29 2006-05-04 Banyu Pharma Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US7737151B2 (en) 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
BRPI0616630B8 (pt) 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
MX2008011769A (es) 2006-03-20 2008-09-25 Hoffmann La Roche Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
WO2007107469A1 (en) 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
WO2010111050A1 (en) * 2009-03-23 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
AU2010229140A1 (en) * 2009-03-24 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
CN104159893B (zh) 2016-05-11
IN2014DN07283A (cg-RX-API-DMAC10.html) 2015-04-24
EP2821406B1 (en) 2016-06-01
MX344276B (es) 2016-12-08
MX2014010395A (es) 2015-06-05
BR112014021519A2 (cg-RX-API-DMAC10.html) 2017-06-20
CA2865875C (en) 2016-06-21
PL2821406T3 (pl) 2016-11-30
AU2013227024A1 (en) 2014-09-18
US20180369224A1 (en) 2018-12-27
JPWO2013129443A1 (ja) 2015-07-30
PT2821406T (pt) 2016-09-07
DK2821406T3 (en) 2016-08-22
CN104159893A (zh) 2014-11-19
KR101677823B1 (ko) 2016-11-18
TWI485146B (zh) 2015-05-21
US10092556B2 (en) 2018-10-09
SG11201405318PA (en) 2014-11-27
WO2013129443A1 (ja) 2013-09-06
BR112014021519B1 (pt) 2022-05-24
CA2865875A1 (en) 2013-09-06
RU2581834C1 (ru) 2016-04-20
HUE028495T2 (hu) 2016-12-28
MY169179A (en) 2019-02-25
JP5323289B1 (ja) 2013-10-23
EP2821406A1 (en) 2015-01-07
US20160228427A1 (en) 2016-08-11
TW201339150A (zh) 2013-10-01
US20150045342A1 (en) 2015-02-12
KR20140129056A (ko) 2014-11-06
US9346787B2 (en) 2016-05-24
EP2821406A4 (en) 2015-04-29
HK1199730A1 (zh) 2015-07-17
ES2576497T3 (es) 2016-07-07

Similar Documents

Publication Publication Date Title
AU2013227024A1 (en) Novel piperidine compound or salt thereof
EP2739618B1 (en) Quinazoline compounds as serine/threonine kinase inhibitors
CN113754653A (zh) 一种kras g12c抑制剂化合物及其用途
CN106170288B (zh) 药物化合物
JP6908536B2 (ja) ムスカリンm2受容体の正のアロステリックモジュレーター
WO2023207556A1 (zh) Prmt5-mta抑制剂
CN111925367A (zh) 稠环类衍生物抑制剂、其制备方法和应用
US9012475B2 (en) Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
WO2024159094A1 (en) Pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases
WO2024097953A1 (en) Naphthyridine compounds for inhibition of raf kinases
KR20220136395A (ko) Irak4 억제제로서 유용한 트리시클릭 헤테로아릴 화합물
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑
HK1199730B (en) Piperidine compound or salt thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)